AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05154019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Minds at Work Online Training
Description: The intervention will be an online, interactive training course which will include evidence-based material, guidance, and practical exercises. The training will cover the following topics, presented as a series of independent, stand-alone modules:~Module one: Looking after your own mental health Module two: Designing and managing work to promote mental well-being Module three: Management Competencies that Prevent Work-related Stress Module four: Developing a Psychologically Safe Workplace Module five: Having conversations about mental health at work Each module will be designed to take between 20 and 30 minutes to complete. Participants will be permitted by their employer to complete the training within their work time. The training is self-led, so each participant can progress through each module at their own pace and at a time that suits them.
Study NCT05816798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: PBM is a therapeutic technique that uses light at different wavelengths (red or infrared), in a non-invasive way in which non-ionizing irradiation is used to produce a series of photophysical and photochemical effects when applied to biological tissues (humans and animals). Regarding the clinical results, numerous articles have already demonstrated the effect of PBM in improving pain and disability in patients with knee joint pain.
Study NCT05816798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy Tretament
Description: standard treatment (physiotherapy-standard exercises: Cardiopulmonary physiotherapy and Physiotherapy with global muscle strengthening exercises). This program will be maintained for all study patients, for both groups, throughout the data collection period and includes activities 2X per week.)
Study NCT05816798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Physiotherapy Tretament
Description: standard treatment (physiotherapy-standard exercises: Cardiopulmonary physiotherapy and Physiotherapy with global muscle strengthening exercises). This program will be maintained for all study patients, for both groups, throughout the data collection period and includes activities 2X per week.)
Study NCT05816798 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation Placebo
Description: The same interventions described of Photobiomodulation Group bu device will be turned off
Study NCT05702801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic Vibratory Stimulation (SVS)
Description: Investigators implement stochastic vibratory stimulation (SVS) to alter proprioceptive performance by increasing excitement of type Ia afferents in muscle spindles. Based on previous preliminary data, vibration frequencies around 40Hz may provide adequate noise for enhancing aging-related proprioceptive deficits. To make a subsensory noise investigators set it to 90% of the sensory threshold amplitude, which has been effectively used previously for influencing mechanoreceptor sensation in older adults. Stimulation will be imposed bilaterally on: 1) distal ankle (tibialis anterior, peroneus longus, soleus, gastrocnemius); and 2) proximal hip (quadriceps, gluteus medius, and paraspinals). Investigators use Gaussian noise to reduce the anticipative and preemptive adjustments of muscle spindles to the vibration. For SVS investigators use a magnetic actuator system and a Universal Controller (C-2HDLF Tactor/TDK), to provide programmable frequency ranges.
Study NCT06002451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEB-BASED PRECONCEPTİONAL CARE AND COUNSELİNG
Description: A web-based preconceptional care and consultancy training platform has been developed. In line with the literature, a comprehensive preconceptional care and counseling training content was prepared for women between the ages of 18-49. Web-based training consists of a total of 9 modules.The videos created for uploading to the website were shot in a professional studio environment with professional equipment.Each video was shot and recorded by dividing the training content according to its subsections, with an average of at least 6 minutes and a maximum of 16 minutes. Each of the module videos is based on giving the main messages in line with the purpose and objectives of the presentation.women were allowed to watch all the videos within 2 weeks. A dialog box is opened on the website where women can communicate with their midwives 24/7. During and after the training, preconceptional care and counseling training was given in this area for a total of 10 weeks.
Study NCT06085326 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smart Checklist
Description: The digitized Smart Checklist includes three new features that currently do not exist on a paper checklist: 1) decision support prompts based on patient-provider dyad characteristics, 2) real time display of patient pertinent airway information from the EHR, and 3) high-risk warning alerts based on predictive analytics with potential explanatory factors from the model.
Study NCT05974488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McMurray Enhanced Airway
Description: The MEA is non-sterile. It can be used in inpatient or outpatient surgery, in hospital or clinic settings, or in an emergency setting. The MEA has five parts: an optional 15 mm connector, flange (color-coded for size), elongated cushioned bite block, flexible cannula, and distal tip, and a channel to allow for passage of air and a suction catheter. The MEA is designed to open and maintain a patient's upper airway. Oxygen will be delivered through the breathing circuit with the following parameters: 40% oxygen at 6 liters/min flow throughout the procedure time. The MEA will be placed in the participant's oropharyngeal airway one time during an in-person visit.
Study NCT05974488 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula
Description: Participants in this group will use the nasal cannula to deliver oxygen as per standard of care one time during the in-person visit.
Study NCT05162625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution
Description: Topical moxifloxacin 0,5% 01 drop every 3 hours
Study NCT05162625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 400 MG/200 ML Intravenous Solution [CIPRO IV]
Description: Intravenous ciprofloxacin 400mg every 12 hours and cefazolin 1000mg every 6 hours
Study NCT06339060 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Experimental: Arm 1 Organ preservation
Description: Arm 1 patients will undergo clinical response evaluations (CREs) after neoadjuvant therapy(A+B+C）, If cancer is detected, surgery will be performed. Patients with clinical complete response （cCR） are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer.Postoperative adjuvant therapy will follow the NCCN guideline.~A: Camrelizumab 200mg IV on days 1 and 22 B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.~A+B+C=Neoadjuvant therapy
Study NCT06339060 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Arm 2 Surgery
Description: Arm 2 patients will undergo surgery after neoadjuvant therapy(B+C）.Postoperative adjuvant therapy will follow the NCCN guideline.~B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.
Study NCT06100900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX10013
Description: Multiple dose levels may be tested in this study.
Study NCT04726410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cold Stored Platelets
Description: early infusion of urgent release CSP
Study NCT04726410 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: standard care including room temperature platelets
Study NCT05131425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facing Your Fears: ASD/ID
Description: This cognitive behavioral therapy, entitled Facing Your Fears for Adolescents with Autism and Intellectual Disability, is focused on somatic management, helpful cognitive mantras, emotion regulation, and graduated exposure adapted for the cognitive and linguistic needs of an Intellectual Disability population.
Study NCT05131425 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: The treatment as usual condition is being used in this study as a control condition. The investigators will track what medication and intervention services families are currently receiving.
Study NCT04390009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Entire-body PET-CT scans
Description: Entire-body PET-CT scans will be performed with state-of-the-art scanners with different manufacturers' models including Siemens Biograph Vision, United Imaging uEXPLORER and possibly other recently FDA-approved PET-CT scanners.
Study NCT04390009 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amyvid radiopharmaceutical
Description: Amyvid (F18-florbetapir) will be evaluated for binding to white matter of the peripheral and central nervous system of participants
Study NCT04848194 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: skin biopsy and blood sampling
Description: * 4 skin biopsies outside the face under local anesthesia: 2 in damaged zone, 2 in non-damage zone.~* A blood sample
Study NCT05249426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))
Study NCT05249426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))
Study NCT05249426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))
Study NCT05249426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab
Study NCT05249426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigator´s Choice Chemotherapy
Description: Allowable chemotherapies include: paclitaxel, docetaxel, capecitabine, 5-fluorouracil, methotrexate or combinations thereof
Study NCT05564104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection as well as intravenously in the form of solution for injection.
Study NCT05628675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby CHAT
Description: Baby CHAT is an approximately 90-minute group intervention to be delivered during pregnancy. The group is comprised of psychoeducational material about a baby's social development after birth and while the baby is growing in the womb. Attendees are encouraged to think about when an infant's social development begins and consider whether this occurs before or after birth. Participants are then shown a video clip of Reissland et al.'s (2016) study showing 4D ultrasound images of foetuses mouthing in response to sounds that are presented to them outside the womb. During Baby CHAT, parents are encouraged to reflect on this information in the context of their own baby's development, including their likes and dislikes, routine and personality. The final section of the group involves generating ideas for social activities that parents can try with their baby prior to birth, such as singing to, massaging or reading to their baby.
Study NCT02919137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
Study NCT05414474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes
Study NCT05414474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 500 mg
Description: Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 500 mg AA
Study NCT05414474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 80 mg
Description: Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe + 80 mg AA
Study NCT05414474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 54Fe isotopes + 150 mL coffee
Study NCT05414474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 57Fe isotopes + 1 bread roll (\~100 g) with butter and honey + 1 cup of plain yoghurt (180 mL) + 1 cup of coffee (150 mL) + 1 glass of orange juice (250 mL)
Study NCT05414474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Afternoon
Description: Ferrum Hausmann 100 mg + 200 mL nanopure water with 3 mg 58Fe isotopes administered in the afternoon
Study NCT06529614 — intervention group
Intervention type: OTHER
Intervention: In-situ detection for Micro-RNA
Description: a new in-situ detection methods for Micro-RNA
Study NCT05751941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: 1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily
Study NCT05751941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg of Enzalutamide will be given orally daily ending at week 4
Study NCT05751941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240 mg of Apalutamide will be given orally daily ending at week 4
Study NCT05751941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.
Study NCT05477134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus
Description: On separate study days, each participant will have a stable isotope infusion, ingest oral glucose, and be given an intravenous arginine bolus.
Study NCT06023589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Participants will be receiving subcutaneous injection of tezepelumab
Study NCT06023589 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be receiving subcutaneous injection of matching placebo
Study NCT05918523 — intervention group
Intervention type: BIOLOGICAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: No interventions in this trial
Study NCT05382923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Light
Description: 3 consecutive days of 1 hour bright light
Study NCT05382923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Light + Exercise + Melatonin
Description: 3 consecutive days of bright light, exercise, and melatonin
Study NCT05382923 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 3 consecutive days of dim red light + light stretching + placbo
Study NCT05164809 — intervention group
Intervention type: DEVICE
Intervention: Application of novel electrodes
Description: Application of novel electrodes since 2017 for the dissection of extremity tumors in tumororthopedics
Study NCT05305209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The patients will receive 12 minutes of intravaginal application with an average power of 1 watios and total applied energy of 720J and an extracavitary application for 4 minutes with an average power of 3 watios and a total dose of 720J with all effects at 200%, twice a week for 6 weeks.
Study NCT06140069 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders.
Study NCT05225688 — intervention group
Intervention type: BEHAVIORAL
Intervention: Bike exertion test
Description: maximal exercise test
Study NCT06253949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ligation of inferior mesenteric artery in colorectal cancer
Description: This study will include two groups of patients: group (A) and (B). In group (A), the inferior mesenteric artery will be ligated at its origin (high-tie), While in group (B), it will be ligated after the origin of the left colic artery (low-tie).
Study NCT04551092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEVR
Description: a non-invasive, non-pharmacological alternative to treat pain by combining an innovative electroencephalography (EEG)-based Neurofeedback solution in an immersive virtual reality (VR) environment.
Study NCT06430801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Tulisokibart
Description: Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
Study NCT06430801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Tulisokibart
Description: Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered intravenously
Study NCT06430801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Tulisokibart
Description: Humanized monoclonal antibody that binds human TL1A, administered subcutaneously
Study NCT06430801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: Placebo matching IV tulisokibart
Study NCT06430801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SC Placebo
Description: Placebo matching SC tulisokibart
Study NCT06430801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SC Placebo
Description: Placebo matching SC tulisokibart
Study NCT05780294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fu
Description: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
Study NCT05780294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fu
Description: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
Study NCT05780294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lobaplatin
Description: 30mg/m2, used on the 1st and 28th day of each cycle.
Study NCT05780294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobaplatin
Description: 30mg/m2, used on the 1st and 28th day of each cycle.
Study NCT05780294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets/dose 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, 3 tablets/dose 3 times daily during chemotherapy, and continued to be given orally 2 tablets/dose 3 times daily for 4 weeks after the end of chemotherapy.
Study NCT05780294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucogen
Description: 40 mg/dose was used 3 times for peri-chemotherapy prophylaxis and inter-chemotherapy period, and 60 mg/dose was used 3 times daily during chemotherapy, and 40 mg/dose was continued orally 3 times daily for 4 weeks after the end of chemotherapy.
Study NCT01909414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEO-D03 DNA Vaccine
Description: DNA GEO-D03 vaccine will be administered as a 3 mg dose IM.
Study NCT01909414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B Vaccine
Description: MVA/HIV62B vaccine will be administered as a 1 x 10\^8 TCID50 dose IM.
Study NCT01909414 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DNA GEO-D03
Description: Placebo for DNA GEO-D03 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
Study NCT01909414 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MVA/HIV62B Vaccine
Description: Placebo for MVA/HIV62B 1 x 10\^8 TCID50 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
Study NCT04765735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-loop testing, Closed-loop testing - External Spinal Cord Stimulator (SCS)
Description: SCS therapy with an external neurostimulator using either open-loop or closed loop algorithm
Study NCT06514963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9813
Description: Specified dose on specified days
Study NCT06514963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT06041516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-701
Description: ADCT-701 in 2microgram/kg-255microgram/kg (weight based dosing), IV over 30 minutes (+15 minutes)
Study NCT06139224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 day prebiotic consumption
Description: 20 HIV-infected ART-suppressed individuals will be provided a with commercially available prebiotic (FOS) for 10 days. Participants will be instructed to consume the prebiotic daily during the first three days and then twice daily for an additional seven days. Participants will be instructed to consume the powder in the morning on the first three days, then in the morning and afternoon for the following week. Each participant will have a baseline visit and a follow up visit after 10 days of the FOS intervention. Blood and stool will be collected at both visits.